ROSE试验中急性呼吸窘迫综合征的分子表型具有不同结局及基线与纵向基因表达模式
该研究在ROSE试验(中重度ARDS患者中使用顺阿曲库铵)中对入组前临床与蛋白生物标志物进行潜类别分析,识别出低炎症表型(60.4%)和高炎症表型(39.6%),高炎症表型第90天死亡率显著更高(61.6% vs 30.3%,P<0.0001)。在134例患者亚组中,对入组时和第2天全血RNA测序,发现高炎症表型第0天富集先天免疫反应、组织重塑和锌代谢相关基因,第2天富集胶原合成和中性粒细胞脱颗粒相关基因。基因表达纵向变化因生存状态而异;多数高表达基因与相应血浆蛋白丰度相关,但潜类别分析中定义类别的血浆蛋白与其对应基因表达无相关性。两种表型与随机分组间无死亡率治疗交互作用。
要点
- ROSE试验中高炎症表型占39.6%,第90天死亡率61.6%,低炎症表型占60.4%,死亡率30.3%(P<0.0001)。
- 两种表型与随机分组(顺阿曲库铵 vs 对照)之间无死亡率治疗交互作用。
- 高炎症表型第0天富集先天免疫反应、组织重塑和锌代谢相关基因,第2天富集胶原合成和中性粒细胞脱颗粒相关基因。
- 基因表达纵向变化模式因生存状态而异。
- 多数高表达基因与相应血浆蛋白丰度相关,但潜类别分析中定义类别的血浆蛋白与其对应基因表达无相关性。
适用人群与场景
- ROSE试验纳入的中重度急性呼吸窘迫综合征患者,入组时间较早。
研究设计与关键结果
- 研究类型:对ROSE试验(中重度ARDS患者使用顺阿曲库铵的试验)进行潜类别分析,使用入组前临床和蛋白生物标志物;在134例患者亚组中,对入组时和第2天样本进行全血RNA测序,行差异基因表达和通路分析,并测量额外血浆蛋白。
- 识别出低炎症表型(60.4%)和高炎症表型(39.6%),其生物学和临床特征与既往研究相似。
- 高炎症表型第90天死亡率61.6%,低炎症表型30.3%(P<0.0001)。
- 两种表型与随机分组之间无死亡率治疗交互作用。
- 高炎症表型第0天富集先天免疫反应、组织重塑和锌代谢相关基因,第2天富集胶原合成和中性粒细胞脱颗粒相关基因。
- 基因表达模式的纵向变化因生存状态而异。
- 多数高表达基因与相应血浆蛋白丰度相关;但潜类别分析中定义类别的血浆蛋白与其对应基因表达无相关性。
证据类型、等级与局限
- 证据类型:对ROSE试验的二次分析(潜类别分析和RNA测序)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持分子表型推进ARDS精准治疗的临床和生物学潜力。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Two molecular phenotypes have been identified in acute respiratory distress syndrome (ARDS). In the ROSE (Reevaluation of Systemic Early Neuromuscular Blockade) trial of cisatracurium in moderate to severe ARDS, we addressed three unanswered questions: 1) Do the same phenotypes emerge in a more severe ARDS cohort with earlier recruitment; 2) Do phenotypes respond differently to neuromuscular blockade? and 3) What biological pathways most differentiate inflammatory phenotypes?Methods: We performed latent class analysis in ROSE using preenrollment clinical and protein biomarkers. In a subset of patients (n = 134), we sequenced whole-blood RNA using enrollment and Day 2 samples and performed differential gene expression and pathway analyses. Informed by the differential gene expression analysis, we measured additional plasma proteins and evaluated their abundance relative to gene expression amounts.Measurements and Main Results: In ROSE, we identified the hypoinflammatory (60.4%) and hyperinflammatory (39.6%) phenotypes with similar biological and clinical characteristics as prior studies, including higher mortality at Day 90 for the hyperinflammatory phenotype (30.3% vs. 61.6%; P < 0.0001). We observed no treatment interaction between the phenotypes and randomized groups for mortality. The hyperinflammatory phenotype was enriched for genes associated with innate immune response, tissue remodeling, and zinc metabolism at Day 0 and collagen synthesis and neutrophil degranulation at Day 2. Longitudinal changes in gene expression patterns differed dependent on survivorship. For most highly expressed genes, we observed correlations with their corresponding plasma proteins' abundance. However, for the class-defining plasma proteins in the latent class analysis, no correlation was observed with their corresponding genes' expression.Conclusions: The hyperinflammatory and hypoinflammatory phenotypes have different clinical, protein, and dynamic transcriptional characteristics. These findings support the clinical and biological potential of molecular phenotypes to advance precision care in ARDS.
参考来源
- Sinha P, Neyton L, Sarma A, et al. Molecular Phenotypes of Acute Respiratory Distress Syndrome in the ROSE Trial Have Differential Outcomes and Gene Expression Patterns That Differ at Baseline and Longitudinally over Time. Am J Respir Crit Care Med. 2024. PMID: 38345571. doi:10.1164/rccm.202308-1490OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。